Post-Market BTVA Registry

Inclusion Criteria: 1. Patients will have heterogeneous emphysema, as evidenced by high-resolution computed tomography (HRCT) demonstrating a heterogeneity index \> or equal to 1.2 in at least one segment to be treated 2. Patients must be \> or equal to 18 years of age 3. Patients are required to provide informed consent prior to inclusion in the Registry Exclusion Criteria: 1. FEV1 \< 20% predicted 2. DLCO \< 20% predicted 3. Inability to walk \> 140 meters in 6 minutes (6MWD) following optimized medical management 4. Unstable COPD (any of the following): 1. \> 3 COPD related hospitalizations requiring antibiotics in past 12 months 2. COPD related hospitalization in past 3 months 3. daily use of systemic steroids, i.e. \> 5 mg prednisolone 5. Concomitant illnesses or medications that would pose a significant increased risk for complications following treatment with InterVapor. Examples of particular relevance include: immune system disorders, immunosuppressant medications of clinical relevance, bleeding disorders and unstable cardiovascular conditions, history of asthma or alpha-1 antitrypsin deficiency 6. Newly prescribed morphine derivatives within the last 4 weeks 7. Pregnant or breastfeeding 8. Highly diseased lower lobes (tissue to air ratio of \<11%) 9. Bacterial infection or symptoms indicative of active infection (i.e., fever, elevated white blood cell count) 10. Presence of single large bulla (defined as \> 1/3 volume of lobe) or a paraseptal distribution of emphysema in the treated lobe 11. Recent respiratory infections or COPD exacerbation in preceding 6 weeks -